Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regadenoson

FDA-approved product (solution, intravenous), marketed as Lexiscan, Regadenoson.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regadenoson
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Myocardial Perfusion Imaging

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other cardiac preparations
FDA pharmacologic class
Adenosine Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regadenoson in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regadenoson with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Regadenoson R-T Perfusion Imaging Trial

    NCT00837369 · start 2009-04-07

    Registered record
    Registry ID
    NCT00837369
    Conditions
    Coronary Artery Disease; Myocardial Perfusion Abnormalities
    Interventions
    Regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04-07
    Completion
    2011-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Myocardial Perfusion Abnormalities
    InterventionRegadenoson
    PhasePhase 1
    Registry statusCompleted

  • Stress Testing and Cardiac Magnetic Resonance

    NCT00871260 · start 2009-04

    Registered record
    Registry ID
    NCT00871260
    Conditions
    Coronary Disease
    Interventions
    regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2014-06-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    Interventionregadenoson
    PhasePhase 4
    Registry statusCompleted

  • Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging

    NCT00857792 · start 2009-03

    Registered record
    Registry ID
    NCT00857792
    Conditions
    Coronary Disease
    Interventions
    regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-03
    Completion
    2013-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    Interventionregadenoson
    PhaseNot applicable
    Registry statusCompleted

  • Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

    NCT00797186 · start 2008-11

    Registered record
    Registry ID
    NCT00797186
    Conditions
    Type 2 Diabetes; Microvascular Dysfunction
    Interventions
    Intensive risk factor management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2008-11
    Completion
    2011-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Microvascular Dysfunction
    InterventionIntensive risk factor management
    PhaseNot applicable
    Registry statusUnknown

  • ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

    NCT00208312 · start 2004-04

    Registered record
    Registry ID
    NCT00208312
    Conditions
    Coronary Artery Disease
    Interventions
    Regadenoson; Adenosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-04
    Completion
    2005-06
    Enrolment
    787

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRegadenoson; Adenosine
    PhasePhase 3
    Registry statusCompleted